# **IMPLEMENTING** PERSONALISED ONCOLOGY

From Experimental to Mainstream: Stakeholder **Elicitation Regarding the Implementation of Personalised Oncology in Dutch Healthcare.** 

### Background



Cancer is responsible for **31%** of the total death rate.

It is a **complex** disease & every patient is unique.



Standard of care treats most cancer patients the same.

Personalised Oncology offers promising tailored treatments.

INTRO: The global evolution of Personalised Oncology (PO) provides examples how stateof-the-art healthcare integrates into patients' lives and serves as a precedent towards widespread future implementation (Singer et al., 2018). The implementation efforts of PO will result in durable clinical benefit, facilitate nationwide access to care and exploit future scientific and technological advances in cancer care (Janssens, Schuster, & Voss, 2018).

PROBLEM: Current initiatives do not contribute to the health of the vast majority of Dutch cancer patients. Many significant barriers to mainstreaming PO exist and implementation is hampered (Joosten et al., 2016); therefore, the healthcare system is not exploiting its potential.

AIM: Develop actionable insights on the implementation of Personalised Oncology in Dutch healthcare by analysing value assessments of stakeholders following allocative decision-making criteria for implementation.

## **Theoretical Framework**

#### **EVIDEM** model for value assessment

#### **Quantitative appraisal**

- **Need for intervention**
- **Comparative outcomes**
- Type of benefit of the intervention
- **Economic consequences**
- **Knowledge of the intervention**

**Qualitative appraisal** 

Normative contextual criteria **Feasibility contextual criteria** 



Author: Victor Bakker ; Supervisor: Kenneth Fernald ; On-site supervisor: Dr. Henk Viëtor & Dr. Coenraad van Kalken ; Presentation date: June 21, 2019. References: Janssens, J. P., Schuster, K., & Voss, A. (2018). Preventive, predictive, and personalized medicine for effective and affordable cancer care. EPMA Journal, 9(2), 113–123. ; Joosten, S.E.P, Retel, V.M.H., van den Heuvel, M.M. & van Harten, W.H. (2016). Scenario drafting for early technology assessment of next generation sequencing in clinical oncology. BMC Cancer. 16 (1).; Singer, F., Irmisch, A., Toussaint, N. C., Grob, L., Singer, J., & Thurnherr, T. et al. (2018). SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics. BMC Medical Informatics and Decision Making, 18(1).

**Feasibility** contextual criteria

**Conclusion & Recommendations** The national implementation of Personalised Oncology will not be feasible yet. To support its effectiveness within cancer care, the healthcare system and all stakeholders have to understand the use of PO and proof its benefit in a clinical setting.

## Study Design (mixed-methods)



Online survey

Medical specialists (N=107)





Stakeholder interviews

(N=8)







Actionable insights & Recommendations

MEDICINE

**EVIDENCE.** 

Ο

BASED

 $\bigcirc \bigcirc \bigcirc$ 

### **Results**

#### **Quantitative data**

### **Need for intervention** 83% high disease burden of cancer

**Type of benefit** of the intervention **31%** PO-based therapy will cure the patient

**Knowledge about** intervention

**54%** not enough supporting scientific evidence

### Qualitative data

Number of patients is growing > ageing population **Difficult to cure** > cancer is N=1

Lack of drugs > unclear rules for administering off-label therapy No treatment is also a treatment > QoL is important > severe side-effects

Few implementation of knowledge > no valuation of implementation quantity > wrong incentives in science

#### **Only qualitative data**

High costs and no investments > no direct cost-benefit relation **No leadership** > no mandate of stakeholders > no one feels responsible **No data governance** > no interoperability > no rules in data (re)use

<sup>44</sup> You will need a radical approach that proves Personalised Oncology really has a therapeutic effect on the patient, rather than shifting the burden of proof. Only then the majority will follow. Policymaker

#### **Recommended** approach:


Create mandate and take leadership within the PO debate. Launch a foundation or an institute to accelerate cancer care. Why? To treat todays' patient with tomorrows care.



Invest & take leading position in genomic research via big data based analysis of Real World Evidence (RWE) (n=1, n=1, n=1)



Develop a platform to mine global treatment options based on PO and match patients to existing therapies



Be responsible for the burden of proof by treating patients with PO-based care; arranged in one clear patient journey